Innovative evolution of cancer gene and cellular therapies

Cancer Gene Therapy

Volumn 20, Issue 3, 2013, Pages 141-149

  Lam, P ^a   Khan, G ^b   Stripecke, R ^c   Hui, K M ^a,d,e   Kasahara, N ^f   Peng, K W ^g   Guinn, B A ^b,h,i  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cancer research; immunotherapy; stem cells

Indexed keywords

CELASTROL; EPIDERMAL GROWTH FACTOR RECEPTOR; LENTIVIRUS VECTOR; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MICROSOMAL AMINOPEPTIDASE; MUCIN 1; RITUXIMAB; T LYMPHOCYTE RECEPTOR; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BIOTECHNOLOGY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE PROGRESSION; CELL STRAIN HEK293; CELL THERAPY; HERPES SIMPLEX VIRUS; HUMAN; LEUKEMIA CELL; MEASLES VIRUS; MELANOMA; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SCID MOUSE; VESICULAR STOMATITIS VIRUS;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA INTERFERENCE; TISSUE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84875211121     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.93     Document Type: Review

References (52)

1. Guinn B, Casey G, Mo ller MG, Kasahara N, OSullivan GC, Peng KW et al. International Society for Cell and Gene Therapy of Cancer 2009 Annual Meeting held in Cork, Ireland. Hum Gene Ther 2010; 21: 9-26.
2. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H et al. P53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007; 6: 1478-1482.
3. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
4. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101-15106.
5. Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK et al. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 2008; 7: 2528-2535.
6. Kim PH, Sohn JH, Choi JW, Jung Y, Kim SW, Haam S et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 2011; 32: 2314-2326.
7. Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012; 18: 6271-6283.
8. Hardwick N, Buchan S, Ingram W, Pulford K, Mufti GJ, Stevenson FK et al. An analogue peptide from the cancer-testis antigen, PASD1, induces CD8+ T cell responses against naturally processed peptide. Submitte.d.
9. Rice J, Buchan S, Stevenson FK. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 2002; 169: 3908-3913.
10. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 2003; 1: E65.
11. Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO et al. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2005; 2: e265.
12. Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2011; 303: 9-20.
13. Cronin M, Stanton RM, Francis KP, Tangney M. Bacterial vectors for imaging and cancer gene therapy: a review. Cancer Gene Ther 2012; 19: 731-740.
14. Cronin M, Akin AR, Collins SA, Meganck J, Kim JB, Baban CK et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One 2012; 7: e30940.
15. Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E et al. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther 2007; 15: 971-980.
16. Pincha M, Salguero G, Wedekind D, Sundarasetty BS, Lin A, Kasahara N et al. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Therapy 2011; 18: 750-764.
17. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
18. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007; 110: 2620-2630.
19. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851.
20. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924.
21. Mesel-Lemoine M, Cherai M, Le Gouvello S, Guillot M, Leclercq V, Klatzmann D et al. Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood 2006; 107: 381-388.
22. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai M et al. CD4CD25 regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.
23. Wells JW, Cowled CJ, Farzaneh F, Noble A. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 2008; 181: 3422-3431.
24. Kim WJ, Christensen LV, Jo S, Yockman JW, Jeong JH, Kim YH et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006; 14: 343-350.
25. Son S, Namgung R, Kim J, Singha K, Kim WJ. Bioreducible polymers for gene silencing and delivery. Acc Chem Res 2012; 45: 1100-1112.
26. Son S, Singha K, Kim WJ. Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier. Biomaterials 2010; 31: 6344-6354.
27. Namgung R, Singha K, Yu MK, Jon S, Kim YS, Ahn Y et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 2010; 31: 4204-4213.
28. Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 7719-7725.
29. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 2007; 13: 6275-6283.
30. Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011; 17: 6040-6051.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. American Association for the Study of Liver Diseases. Hepatology 2011; 53: 1020-1022.
32. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
33. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-1709.
34. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
35. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
36. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
37. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010; 5: 2044-2046.
38. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
39. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-6020.
40. Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE et al. Decentral gene expression analysis for ER/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012; 460: 251-259.
41. Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother 2010; 59: 379-388.
42. Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N et al. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. Br J Haematol 2009; 145: 749-760.
43. Hasegawa K, Pham L, OConnor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006; 12: 1868-1875.
44. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-882.
45. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 2012; 26: 1870-1878.
46. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
47. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-1904.
48. Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 2008; 113: 1332-1337.
49. Logg CR, Robbins JM, Jolly DJ, Gruber HE, Kasahara N. Retroviral replicating vectors in cancer. Methods Enzymol 2012; 507: 199-228.
50. Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology 2012; 14: 145-159.
51. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
52. Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011; 19: 1170-1179.